Global, Regional, and National Burden of Benign Prostatic Hyperplasia from 1990 to 2021 and Projection to 2035

Overview

Journal BMC Urol

Publisher Biomed Central

Specialty Urology

Date 2025 Feb 19

PMID 39972318

Authors

Hui Wei

Cong Zhu

Qiao Huang

Jun Yang

Yi-Tong Li

Yin-Gang Zhang

Bing-Hui Li

Hao Zi

Affiliations

Soon will be listed here.

Abstract

Background: Benign prostatic hyperplasia (BPH) is a common male urological disease around the world. This study aimed to evaluate global, regional, and national burden of BPH from 1990 to 2021, and to forecast the incidence and prevalence of BPH to 2035.

Methods: Using the data and methods of the Global Burden of Disease 2021, we presented the incidence, prevalence, and disability-adjusted life-years (DALYs) of BPH from 1990 to 2021. The trends of burden over time were assessed using estimated annual percentage changes. We applied Bayesian age-period-cohort model to forecast the incidence and prevalence of BPH to 2035.

Results: In 2021, the global number of incident cases, prevalent cases, and DALYs of BPH were 137.88, 1125.02, and 22.36 per 100,000 populations, respectively. From 1990 to 2021, the age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), and age-standardized DALYs rate (ASDR) of BPH remained stable. The highest ASIR, ASPR, and ASDR were recorded in Eastern Europe in 2021. Nationally, China had the highest number of incident cases, prevalent cases, and DALYs of BPH. With the increase of socio-demographic index, the trends of ASIR, ASPR, and ASDR all exhibit an initial rise followed by a gradual decline. The global incidence and prevalence are expected to increase from 962.42 to 7878.68 per 100,000 populations in 2022 to 998.55 and 8620.60 per 100,000 populations in 2035, respectively.

Conclusions: The persistent burden of BPH continues to pose a critical public health challenge. The escalating prevalence among middle-aged and elderly populations underscores the imperative to tackle this widespread condition.

References

Wang Y, Yang L, Deng Y, Yan S, Luo L, Chen P . Causal relationship between obesity, lifestyle factors and risk of benign prostatic hyperplasia: a univariable and multivariable Mendelian randomization study. J Transl Med. 2022; 20(1):495. PMC: 9617448. DOI: 10.1186/s12967-022-03722-y. View

. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403(10440):2100-2132. PMC: 11126520. DOI: 10.1016/S0140-6736(24)00367-2. View

Riebler A, Held L . Projecting the future burden of cancer: Bayesian age-period-cohort analysis with integrated nested Laplace approximations. Biom J. 2017; 59(3):531-549. DOI: 10.1002/bimj.201500263. View

Zhu C, Wang D, Zi H, Huang Q, Gu J, Li L . Epidemiological trends of urinary tract infections, urolithiasis and benign prostatic hyperplasia in 203 countries and territories from 1990 to 2019. Mil Med Res. 2021; 8(1):64. PMC: 8656041. DOI: 10.1186/s40779-021-00359-8. View

Lee S, Chan E, Lai Y . The global burden of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A systematic review and meta-analysis. Sci Rep. 2017; 7(1):7984. PMC: 5554261. DOI: 10.1038/s41598-017-06628-8. View

Zi H, He S, Leng X, Xu X, Huang Q, Weng H . Global, regional, and national burden of kidney, bladder, and prostate cancers and their attributable risk factors, 1990-2019. Mil Med Res. 2021; 8(1):60. PMC: 8611255. DOI: 10.1186/s40779-021-00354-z. View

Gravas S, de la Rosette J . Investigational therapies targeted to the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2013; 22(3):357-68. DOI: 10.1517/13543784.2013.761973. View

Liu D, Li C, Li Y, Zhou L, Li J, Wang Y . Benign prostatic hyperplasia burden comparison between China and United States based on the Global Burden of Disease Study 2019. World J Urol. 2023; 41(12):3629-3634. DOI: 10.1007/s00345-023-04658-8. View

Welch G, Weinger K, Barry M . Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology. 2002; 59(2):245-50. DOI: 10.1016/s0090-4295(01)01506-0. View

10.

Launer B, McVary K, Ricke W, Lloyd G . The rising worldwide impact of benign prostatic hyperplasia. BJU Int. 2020; 127(6):722-728. PMC: 8170717. DOI: 10.1111/bju.15286. View

11.

Murray C . The Global Burden of Disease Study at 30 years. Nat Med. 2022; 28(10):2019-2026. DOI: 10.1038/s41591-022-01990-1. View

12.

Guo X, Yang J, Wu L, Fang C, Gu J, Li F . Periodontitis relates to benign prostatic hyperplasia via the gut microbiota and fecal metabolome. Front Microbiol. 2024; 14:1280628. PMC: 10756679. DOI: 10.3389/fmicb.2023.1280628. View

13.

. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a.... Lancet. 2024; 403(10440):2133-2161. PMC: 11122111. DOI: 10.1016/S0140-6736(24)00757-8. View

14.

Chughtai B, Forde J, Thomas D, Laor L, Hossack T, Woo H . Benign prostatic hyperplasia. Nat Rev Dis Primers. 2016; 2:16031. DOI: 10.1038/nrdp.2016.31. View

15.

Speakman M, Kirby R, Doyle S, Ioannou C . Burden of male lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) - focus on the UK. BJU Int. 2014; 115(4):508-19. DOI: 10.1111/bju.12745. View

16.

Li L, Han J, Wu L, Fang C, Li W, Gu J . Alterations of gut microbiota diversity, composition and metabonomics in testosterone-induced benign prostatic hyperplasia rats. Mil Med Res. 2022; 9(1):12. PMC: 8962033. DOI: 10.1186/s40779-022-00373-4. View

17.

Egan K . The Epidemiology of Benign Prostatic Hyperplasia Associated with Lower Urinary Tract Symptoms: Prevalence and Incident Rates. Urol Clin North Am. 2016; 43(3):289-97. DOI: 10.1016/j.ucl.2016.04.001. View

18.

Xu X, Liu G, Guo Y, Zhu H, He D, Qiao X . Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Mens Health. 2021; 15(4):15579883211036786. PMC: 8326634. DOI: 10.1177/15579883211036786. View

19.

Huang Q, Li B, Wang Y, Zi H, Zhang Y, Li F . Clinical biomarker-based biological aging and risk of benign prostatic hyperplasia: A large prospective cohort study. Aging Med (Milton). 2024; 7(3):393-405. PMC: 11222739. DOI: 10.1002/agm2.12331. View

20.

Stroup S, Palazzi-Churas K, Kopp R, Parsons J . Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int. 2011; 109(1):84-7. DOI: 10.1111/j.1464-410X.2011.10250.x. View